Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA)
Blood（2011）
摘要
Abstract 6
更多查看译文
关键词
gemtuzumab ozogamicin,acute leukemia,acute leukemia french association,standard chemotherapy,event-free,newly-diagnosed
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要